What is CBC and what does it do?

Cannabichromene (CBC) is one of the six major cannabinoids found in cannabis plants, typically comprising 0.3% or less of the total cannabinoid profile in most strains. Discovered in 1966, CBC is a non-intoxicating compound that shares the same molecular formula as THC and CBD (C21H30O2) but has a different structural arrangement. Unlike THC, CBC does not bind strongly to CB1 receptors in the brain, which is why it doesn't produce psychoactive effects. Instead, CBC interacts with other receptors in the endocannabinoid system, including TRPV1 and TRPA1 receptors, which are involved in pain perception and inflammation. Preliminary research suggests CBC may have several potential therapeutic properties. Studies indicate it might support neurogenesis (the growth of new brain cells), with research showing CBC increased the viability of neural stem progenitor cells. Animal studies have also explored CBC's potential anti-inflammatory, antimicrobial, and analgesic properties. CBC appears to work synergistically with other cannabinoids in what researchers call the "entourage effect." When combined with THC and CBD, CBC may enhance the overall therapeutic potential of cannabis products. Some studies suggest CBC works particularly well with CBD, potentially amplifying anti-inflammatory effects. Currently, CBC-dominant strains are rare in the commercial market, as most cannabis cultivars produce minimal amounts of this cannabinoid. However, some specialized breeders are developing CBC-rich varieties, with concentrations reaching 1-2% in select strains. **Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare professional before using cannabis products for any health condition. Cannabis research is still evolving, and more studies are needed to fully understand CBC's effects and potential benefits.**